This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche Buys NLRP3 Inflammasome Inhibitors Developer Inflazome
by Zacks Equity Research
Roche (RHHBY) buys Inflazome for ???euro 380 million and gains access to pipeline of small molecule NLRP3 inhibitors.
The Zacks Analyst Blog Highlights: JPM, PYPL, NVO, RHHBY and TM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPM, PYPL, NVO, RHHBY and TM
Roche's Tecentriq + Avastin Gets Positive CHMP Opinion for HCC
by Zacks Equity Research
Roche's (RHHBY) combination of immuno-oncology drug, Tecentriq, and Avastin gets positive CHMP opinion for the treatment of advanced or unresectable HCC.
Company News for Sep 21, 2020
by Zacks Equity Research
Companies in the news are: RHHBY, PIC, IMMP, JAX
ChemoCentryx's NDA for Autoimmune Disease Drug Accepted by FDA
by Zacks Equity Research
The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.
Roche's Actemra Meets Goal in Phase III Coronavirus Study
by Zacks Equity Research
Roche's (RHHBY) phase III study, EMPACTA, evaluating Actemra in patients with COVID-19-associated pneumonia, meets primary endpoint.
Top Analyst Reports for JPMorgan, PayPal & Novo Nordisk
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), PayPal (PYPL) and Novo Nordisk (NVO).
Bristol-Myers' Opdivo+Yevroy Application Gets EMA Validation
by Zacks Equity Research
Bristol Myers Squibb (BMY) gets EMA validation for a type II variation application for its Opdivo+Yervoy combination to treat previously untreated, unresectable malignant pleural mesothelioma.
OPKO Health Initiates Mid-Stage Study on Coronavirus Therapy
by Zacks Equity Research
OPKO Health (OPK) is developing its marketed drug, Rayaldee, as a potential treatment for patients with mild-to-moderate COVID-19.
Seattle Genetics Up on Two New Oncology Deals With Merck
by Zacks Equity Research
Seattle Genetics (SGEN) strikes a couple of deals with Merck to co-develop ladiratuzumab vedotin for breast cancer and other solid tumors. Also, Merck will market the company's Tukysa in some places.
Regeneron's Cocktail for Coronavirus Selected for RECOVERY Study
by Zacks Equity Research
Regeneron's (REGN) investigational anti-viral antibody cocktail, REGN-COV2, has been selected for evaluation in the RECOVERY study.
Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug
by Zacks Equity Research
Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East and Latin America
Novartis Reports Positive Data on Beovu for DME Indication
by Zacks Equity Research
Novartis (NVS) announces positive data on Beovu from an ongoing late-stage study for the DME indication.
Pharma Stock Roundup: AZN & PFE's Coronavirus Vaccine Updates & FDA Approvals
by Kinjel Shah
AstraZeneca (AZN) halts coronavirus vaccine study. FDA approves Roche (RHHBY) and Glaxo's (GSK) medicines.
Roche Expands Multiple Sclerosis Portfolio, Starts Studies
by Zacks Equity Research
Roche (RHHBY) expands its MS portfolio by adding pipeline candidate, fenebrutinib. The company also initiates MS studies on fenebrutinib and Ocrevus.
Novartis (NVS) Releases Positive Data on Enerzair Breezhaler
by Zacks Equity Research
Novartis (NVS) posts favorable data on asthma treatment Enerzair Breezhaler at the ERS International Congress 2020.
Here's Why AstraZeneca (AZN) Stock is Up This Year So Far
by Zacks Equity Research
AstraZeneca's (AZN) shares are up this year mainly due to rapid progress in its efforts to make a vaccine to treat COVID-19 as well as other positive pipeline and regulatory updates.
AbbVie Partners With Chinese Biotech for Cancer Candidate
by Zacks Equity Research
AbbVie (ABBV) signs a collaboration agreement with China's I-Mab for developing/commercializing the latter's lemzoparlimab to address various cancer types.
Roche Gets FDA Nod for Gavreto for RET Fusion-Positive NSCLC
by Zacks Equity Research
Roche's (RHHBY) lung cancer arm gets a boost with the FDA approval of Gavreto for NSCLC.
The Zacks Analyst Blog Highlights: Walmart, Roche and Chevron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Roche and Chevron
Top Stock Reports for Walmart, Roche & Chevron
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), Roche Holding (RHHBY) and Chevron (CVX).
Sanofi's Kevzara Fails as a Potential COVID-19 Treatment
by Zacks Equity Research
Sanofi's (SNY) phase III study evaluating Kevzara in severely or critically ill patients hospitalized with COVID-19 fails to meet primary endpoint and key secondary endpoint.
Gilead's Veklury Gets FDA Nod for Expanded Use in Coronavirus
by Zacks Equity Research
Gilead's (GILD) Veklury can now be used to treat all hospitalized patients with COVID-19, in addition to severe COVID-19.
Glaxo Receives EU Approval for Multiple Myeloma Drug Blenrep
by Zacks Equity Research
The European Commission lends a nod to Glaxo's (GSK) Blenrep as a monotherapy for patients with relapsed/refractory multiple myeloma, having received at least four previous therapies.
PTC Therapeutics Gets First Milestone Payment for SMA Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) gets first commercial milestone payment from Roche for first commercial sale of Evrysdi in the United States.